Trusted resource of information on Anxiety & Depression that includes articles, news, videos, animations, quizzes, ...

SZA Last week Weeks at no. 1 Weeks on chart Top Dawg/RCA/Sony Music Week of February 1, 2025 click to see more Top Dawg/RCA/Sony Music Rimas/Sony Music ...

Esketamine is also more potent, so it can be used at lower doses. (Ketamine, although most often used as an anesthetic, can be provided off-label for depression.) It's unclear exactly how esketamine ...

They’ve studied and administered it in controlled, clinical settings to help with treatment-resistant depression and other conditions. Esketamine may be an option for people with major ...

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with severe depression, the FDA says. Here's what that means.

PHOENIX (AZFamily) — A ketamine-derived nasal spray is now available for the millions of Americans living with severe depression ... and initiate the esketamine, the Spravato, without continuing ...

It has been growing in popularity and investigation as a depression treatment in recent years. The drug is available as an intravenous infusion or an intranasal product called Spravato (esketamine) ...

Greenbrook treatment centers also offer SPRAVATO® (esketamine) CIII Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (TRD) in adults as ...

This decision expands the indication of esketamine, offering new hope for patients with treatment-resistant depression(1 Trusted Source FDA approves new nasal spray medication for treatment ...

Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal spray Spravato as the first stand-alone therapy for adults with treatment-resistant depression. The Food and Drug Administration’s ...

There are a significant number of words, phrases and acronyms that appear when talking about race and ethnicity which often change depending on the context of the conversation. Language is ...

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...